These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32376505)

  • 1. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
    Vande Casteele N; Jairath V; Jeyarajah J; Dulai PS; Singh S; Shackelton LM; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1209-1217.e2. PubMed ID: 32376505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
    Dulai PS; Singh S; Vande Casteele N; Meserve J; Winters A; Chablaney S; Aniwan S; Shashi P; Kochhar G; Weiss A; Koliani-Pace JL; Gao Y; Boland BS; Chang JT; Faleck D; Hirten R; Ungaro R; Lukin D; Sultan K; Hudesman D; Chang S; Bohm M; Varma S; Fischer M; Shmidt E; Swaminath A; Gupta N; Rosario M; Jairath V; Guizzetti L; Feagan BG; Siegel CA; Shen B; Kane S; Loftus EV; Sandborn WJ; Sands BE; Colombel JF; Lasch K; Cao C
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2952-2961.e8. PubMed ID: 32062041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.
    Dulai PS; Wong ECL; Reinisch W; Colombel JF; Marshall JK; Narula N
    Inflamm Bowel Dis; 2022 Oct; 28(10):1555-1564. PubMed ID: 34967397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
    Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.
    Papamichael K; Van Stappen T; Vande Casteele N; Gils A; Billiet T; Tops S; Claes K; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):543-9. PubMed ID: 26681486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Aliment Pharmacol Ther; 2018 Feb; 47(4):478-484. PubMed ID: 29210094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
    Brandse JF; Mathôt RA; van der Kleij D; Rispens T; Ashruf Y; Jansen JM; Rietdijk S; Löwenberg M; Ponsioen CY; Singh S; van den Brink GR; D'Haens GR
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):251-8.e1-2. PubMed ID: 26545802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
    Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
    J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2024 Mar; 30(3):370-381. PubMed ID: 37116893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
    Ma C; Sandborn WJ; D'Haens GR; Zou G; Stitt LW; Singh S; Ananthakrishnan AN; Dulai PS; Khanna R; Jairath V; Feagan BG
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1760-1768.e1. PubMed ID: 31546056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.
    Ma C; Jeyarajah J; Guizzetti L; Parker CE; Singh S; Dulai PS; D'Haens GR; Sandborn WJ; Feagan BG; Jairath V
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):447-454.e1. PubMed ID: 33279779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
    Singh S; Proudfoot JA; Dulai PS; Xu R; Feagan BG; Sandborn WJ; Jairath V
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):424-431.e7. PubMed ID: 31108227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.